

Rain Therapeutics Announces an Oral Presentation at the Connective Tissue Oncology Society Annual Meeting

NEWARK, Calif., November 17, 2022 (GLOBENEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced an oral presentation at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place on November 16-19, 2022 in Vancouver, BC, Canada.

Presentation Title: [Sustained disease control with MDM2 inhibitor milademetan in patients with advanced dedifferentiated liposarcoma](#)

Session: Session 3: Medical & Pediatric Oncology and Clinical Trials

Presenter: Mrinal M. Gounder, M.D., Associate Attending Physician
Memorial Sloan Kettering Cancer Center and Weill Cornell
Medical Center, New York, NY, USA

Session Date and Time: Thursday, November 17, 2022; 1:00-2:30 pm Pacific Time

Location: VCC: East Exhibition Hall B

A copy of the presentation materials can be accessed by visiting the "[Resources](#)" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. Rain's lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Investor Contact

Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com

Media Contact

Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com